1.8700 0.00 (0.00%)
After hours: 4:12PM EDT
|Bid||1.8600 x 46000|
|Ask||1.8700 x 36100|
|Day's Range||1.8600 - 1.9500|
|52 Week Range||1.7600 - 12.3100|
|Beta (3Y Monthly)||2.31|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 25, 2019 - Jul 29, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.83|
NEW YORK, NY / ACCESSWIRE / June 3, 2019 / Pomerantz LLP is investigating claims on behalf of investors of ImmunoGen, Inc. ("ImmunoGen" or the "Company") (IMGN). Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext. The investigation concerns whether ImmunoGen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
ImmunoGen (IMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
After two successive weeks of losses, biotech stocks slowly clawed back. Multiple conference presentations, independent clinical trial readouts and a few FDA decisions marked the key events in the biotech ...
Benzinga has examined prospects for many investor favorite stocks over the past week. Bearish calls included biotechs and a recent IPO. Furthermore, investors also saw mixed economic numbers, as well as positive surprises in quarterly reports and initial public offerings, bad news for a market darling from the Supreme Court, and fresh news for whale watchers.
FDA advises ImmunoGen (IMGN) to conduct a phase III study to evaluate the safety and efficacy of lead candidate - mirvetuximab soravtansine.
Why Did Immunogen Stock Crash on May 15?(Continued from Prior Part)Recent share price movementsOn May 15, Immunogen (IMGN) issued a press release announcing mature data from its FORWARD II expansion cohort, which is evaluating the combination of
Why Did Immunogen Stock Crash on May 15?Recent regulatory updateOn May 15, Immunogen (IMGN) issued a press release announcing the FDA’s recommendation to conduct a new Phase 3 trial evaluating mirvetuximab soravtansine monotherapy in high folate
Results to be Presented at 2019 ASCO Annual Meeting
plunged more than 30% on Wednesday after the company revealed that the U.S. Food and Drug Administration has recommended further trials to "evaluate the safety and efficacy" of one of its cancer-fighting treatments. ImmunoGen said in statement that it had requested a meeting with FDA officials to discuss the results of its Phase 3 FORWARD I trial and a potential path to registration for mirvetuximab monotherapy - a treatment it has been developing for patients with certain forms of ovarian cancer. In response, the FDA told ImmunoGen that because the data results produced to date have not been able to meet expectations, "... the study could not be used to support an application for accelerated approval," ImmunoGen said in a statement.
Shares of ImmunoGen, Inc. fell 32% in premarket trade Wednesday after the company said the U.S. Food and Drug Administration recommended conducting a new Phase 3 trial of its ovarian cancer drug, mirvetuximab soravtansine. A recent trial looking at the drug as an ovarian cancer therapy did not meet its primary endpoint. ImmunoGen met with the FDA this past week to discuss the trial and a potential path forward, and the agency provided guidance on trial design and endpoints, the company said. "Our meeting with FDA enabled us to clarify a regulatory path forward for mirvetuximab and we are evaluating all avenues to bring this promising therapy to ovarian cancer patients," Immunogen Chief Executive Mark Enyedy said in a statement. The Waltham, Mass.-based biotech has been working on mirvetuximab as a potential treatment for patients with ovarian cancer who haven't responded to platinum treatment and who also test positive for high folate receptor α. Shares of the biotech have fallen 34% so far this year through Tuesday, while the S&P 500 has gained 13%.
ImmunoGen, Inc., (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the United States Food and Drug Administration (FDA) has recommended that the Company conduct a new Phase 3 randomized trial to evaluate the safety and efficacy of mirvetuximab soravtansine in patients with high folate receptor alpha (FRα)-positive, platinum-resistant ovarian cancer as part of a Type C meeting held this week. ImmunoGen requested the meeting to discuss the results of the Phase 3 FORWARD I trial and a potential path to registration for mirvetuximab monotherapy. FDA acknowledged that platinum-resistant ovarian cancer is a disease with unmet need, provided guidance regarding the design and endpoints of a potential registration study, and encouraged the Company to return to discuss a proposed study design.
The elite funds run by legendary investors such as David Tepper and Dan Loeb make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don't follow. Because of their pay structures, they have strong incentives to do the research necessary […]
ImmunoGen (IMGN) delivered earnings and revenue surprises of 3.23% and -14.13%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 30 cents. The results topped Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment ...
Encouraging Efficacy Signal Observed in Pre-Specified Subset of Patients in Phase 3 FORWARD I Study; Company to Meet with Regulators this Quarter to Discuss Potential Path Forward